FCSC Fibrocell Science Inc.

0  0%
Previous Close 2.02
Price To Book 3.26
Market Cap 19,711,831
Shares 9,758,332
Volume 0
Short Ratio
Av. Daily Volume 911,920

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued December 18, 2009. Approved June 22, 2011.
Phase 2 endpoints not met - June 2016
Chronic Dysphonia
Phase 3 trial to commence 2Q 2019 with data due 4Q 2020.
Recessive dystrophic epidermolysis bullosa
Phase 1 part of trial to complete enrolment 3Q 2019. Data due mid-2020.

Latest News

  1. Savara Plunges on Failure of Late-Stage Study on Molgradex
  2. Fibrocell Up on FDA Designation for Gene Therapy Candidate
  3. Fibrocell to Present at BIO International Convention 2019
  4. Is Fibrocell Science (FCSC) Stock Outpacing Its Medical Peers This Year?
  5. Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB
  6. The Zacks Analyst Blog Highlights: Limbach, Health Insurance, Fibrocell, Camden and First Business
  7. Fibrocell (FCSC) Miss Estimates for Earnings & Revenues in Q1
  8. Small Business Optimism Hits 4-Month High in April: 5 Picks
  9. Fibrocell Reports First Quarter 2019 Financial Results and Recent Operational Highlights
  10. Is Fibrocell Science (FCSC) Outperforming Other Medical Stocks This Year?
  11. Blueprint Medicines (BPMC) Q1 Earnings & Sales Lag Estimates
  12. Global Blood (GBT) Reports Narrower-Than-Expected Loss in Q1
  13. Agenus (AGEN) Q1 Earnings Beat Estimates, Revenues Miss
  14. Spectrum Pharma (SPPI) Q1 Earnings Lag Estimates, Revenues Nil
  15. Puma Biotech (PBYI) Q1 Earnings Top, Nerlynx Disappoints
  16. Intrexon (XON) Reports In-Line Q1 Loss, Misses on Revenues
  17. Horizon Therapeutics' (HZNP) Q1 Earnings Beat Estimates
  18. Amicus' (FOLD) Earnings & Revenues Miss Estimates in Q1
  19. IVERIC bio's (ISEE) Q1 Loss Narrows, Gene Therapy in Focus
  20. Sarepta (SRPT) Q1 Earnings Top Estimates, Exondys 51 Sales Up